Doubts are growing about whether the world’s emergency stockpile of 300,000 Ebola vaccine doses is enough to control future epidemics. Supply of the Merck shot, which is currently being used to fight [Read more]
The Centers for Disease Control and Prevention (CDC) works with its partners to monitor health, detect and investigate health problems, conduct research to enhance and implement prevention strategies, develop and promote sound [Read more]
Tulane University researchers are developing a vaccine formulation that may provide longer lasting immunity in fewer doses against pertussis, more commonly known as “whooping cough.” Microbiologist Lisa Morici, PhD, and immunologist James McLachlan, PhD, [Read more]
The 8th Federation of Infectious Diseases Societies of Southern Africa FIDSSA Congress 2019 will be held at the Indaba Hotel and Conference Centre, Johannesburg, South Africa from 7-9 November 2019. This biennial [Read more]
According to a new survey conducted online by The Harris Poll, commissioned by CareDox and Families Fighting Flu, most Americans (85 percent) understand that otherwise healthy children can die from the flu, [Read more]
The RTS,S vaccine (Mosquirix), approved by the European Medical Agency, has shown partial effectiveness – 31% in 6 to 12 weeks-old infants, and 56% in children aged 5 to 17 months. ISGlobal [Read more]
In a new article published in The Lancet, experts review the current field of Ebola vaccine candidates and clinical trials and highlight key gaps in knowledge that need to be addressed by [Read more]
Vaccinations have begun in a first-in-human trial of an experimental Zika virus vaccine, the National Institute of Allergy and Infectious Diseases (NIAID) announced today. The experimental vaccine, known as rZIKV/D4Δ30-713, was developed [Read more]
Soligenix, Inc. announced on July 9 that it has received notice of allowance for European and Canadian patent applications further extending protection around ThermoVax® including coverage of the Company’s ricin toxin vaccine, [Read more]
The National Institute of Allergy and Infectious Diseases (NIAID) is developing a strategic framework to advance tuberculosis (TB) research and development for the next five years and beyond. The NIAID TB Strategic [Read more]
© 2019 STEMAR MEDIA